Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Broad regulator support encourages WHO to pursue 'biological qualifier' plan

This article was originally published in Scrip

Executive Summary

The World Health Organization is pressing on with its proposal for a "biological qualifier" (BQ) after its group of experts decided the plan had garnered sufficient support from stakeholders including drug regulatory authorities and industry.

You may also be interested in...



EMA Prepares Approval Verdict On Beovu, Idhifa, Recarbrio

Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.

New EU Commissioner Outlines Plans To Tackle Shortages

The EU’s new health commissioner, Stella Kyriakides, has outlined the commission’s plans for dealing with medicines access issues in the EU member states. They include completing the review of the EU pediatric and orphan legislation and developing a new strategic plan to tackle shortages and affordability problems next year.

Scottish HTA body OKs Lynparza For Earlier Use In Ovarian Cancer

AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.

Topics

UsernamePublicRestriction

Register

SC028587

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel